TwinBeech Capital’s Viking Therapeutics VKTX Stock Holding History

TwinBeech Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-56,100	Closed	-$1.83M	–	706
2026 Q1	$1.83M	Buy	+56,100	New	+$1.8M	0.19%	159
2025 Q3	–	Sell	-46,487	Closed	-$1.23M	–	871
2025 Q2	$1.23M	Sell	46,487 -215,706	-82%	-$5.68M	0.03%	387
2025 Q1	$6.33M	Buy	+262,193	New	+$8.29M	0.11%	215
2024 Q4	–	Sell	-105,682	Closed	-$6.69M	–	946
2024 Q3	$6.69M	Buy	+105,682	New	+$6.2M	0.13%	192
2024 Q1	–	Sell	-78,947	Closed	-$1.47M	–	873
2023 Q4	$1.47M	Sell	78,947 -133,586	-63%	-$1.75M	0.02%	448
2023 Q3	$2.35M	Buy	+212,533	New	+$3.04M	0.05%	389

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

TwinBeech Capital's VKTX Position: Q2 2026 in Review

TwinBeech Capital sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 56,100 shares — an estimated $1.83M sold.

TwinBeech Capital first reported a position in VKTX in Q3 2023 and held it in 6 quarters. The position peaked at $6.69M in Q3 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

TwinBeech Capital reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
TwinBeech Capital sold 56,100 Viking Therapeutics shares in Q2 2026, an estimated $1.83M.
TwinBeech Capital first reported a position in Viking Therapeutics in Q3 2023 and held it in 6 quarters.
TwinBeech Capital's Viking Therapeutics position peaked at $6.69M in Q3 2024.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on TwinBeech Capital's 13F filing for Q2 2026, filed 14 Aug 2026.